Akums launches advanced antibiotic Aztreonam-Avibactam to tackle drug-resistant infections

image credit- freepik

Akums Drugs & Pharmaceuticals, a Delhi-based Contract Development and Manufacturing Organization (CDMO), has announced the launch of Aztreonam-Avibactam Injection, an advanced antibiotic therapy aimed at treating multidrug-resistant gram-negative bacterial infections.

The therapy is designed for severe and life-threatening infections that show limited or no response to conventional antibiotics, particularly in intensive care settings.

“The rise of antimicrobial resistance has significantly reduced the effectiveness of conventional therapies,” said Sanjeev Jain, Managing Director, Akums. “Aztreonam-Avibactam represents an important advancement in addressing infections caused by highly resistant pathogens, especially where timely and effective intervention is critical.”

Multidrug-resistant infections, often referred to as “superbugs,” are commonly linked to conditions such as hospital-acquired pneumonia, complicated intra-abdominal infections, and severe urinary tract infections, posing significant challenges in clinical management. Aztreonam-Avibactam combines aztreonam, a monobactam antibiotic active against gram-negative bacteria, with avibactam, a beta-lactamase inhibitor that protects the antibiotic from enzymatic degradation. This dual-action mechanism enhances its effectiveness against resistant bacterial strains, enabling it to target pathogens that have developed resistance to multiple drug classes.

The product is manufactured at Akums’ state-of-the-art injectable facility in Kotdwar, Uttarakhand, designed to meet stringent global regulatory standards for complex sterile formulations. The development is further supported by the company’s dedicated Penem facility, a specialised infrastructure built to handle high-potency and advanced antibiotic formulations.

The therapy holds significant relevance in critical care settings, where delays or suboptimal treatment can have serious implications for patient outcomes. Clinical evidence indicates that the combination is well tolerated, with no major treatment-related adverse events reported, reinforcing its potential in managing complex, multidrug-resistant infections.